Ingrid Glimelius

Professor at Department of Immunology, Genetics and Pathology, Cancer Precision Medicine; Research group Ingrid Glimelius

Mobile phone:
+46 70 2253912
Visiting address:
Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Postal address:
Akademiska sjukhuset, ingång 100/101
751 85 Uppsala

Short presentation

Senior Consultant and Associate Professor at the Oncology Clinic, Uppsala University Hospital. I conduct both clinical trials and large register-based investigations with a specific focus on Mantle Cell Lymphoma.

I am also affiliated to the Clinical Epidemiology Unit, Karolinska Institutet.

I study etiology, prognosis and late-effects (childbearing) in patients burdened by lymphatic malignancies.

My research projects also cover many translational projects at the Pathology Department.

Keywords: hodgkin lymphoma survivorship ovarian cancer testicular cancer childbirth after cancer mantle cell lymphoma cancer epidemiology

MD, Uppsala University 2001

PHD, Uppsala University 2009, Hodgkin lymphoma – an interplay between tumour cell and microenvironment

MD, specialist Internal Medicine 2011

MD, specialist Oncology 2013

Associate Professor in Oncology 2016

Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017

Senior Consultant Oncology 2019

Senior lecturer 2021

Hodgkin lymphoma

Hodgkin lymphoma affects young adults and is today a curable disease with intensive chemotherapy. In this recent article, published in Journal of Clinical Oncology, the childbearing potential in survivors after Hodgkin lymphoma have been investigated together with researcher at Karolinska Institutet Caroline Weibull. We show that in the absence of relapse, contemporarily treated women have an improved childbearing potential with calendar time and women treated today give birth to the same degree as matched comparators.

In a related publication in Journal of Clinical Oncology from 2016 we have earlier shown the safety of having children for female survivors, were there was no increased risk of relapse after a pregnancy

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.

Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I. J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514. [Epub ahead of print] PMID: 30044694

Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.

Weibull CE, Eloranta S, Smedby K, Björkholm M, Kristinsson SY, Johansson AL, Dickman PW, Glimelius I. J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14. PMID: 26668344

Nodular lymphocyte predominant Hodgkin lymphoma

We have recently started a joint Nordic collaboration investigating the outcome and late effects for patients burdened by the rare subtype Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Mantle Cell Lymphoma

Mantle cell lymphoma is today one of the lymphomas with poor prognosis. I am national principal investigator in the ENRICH-trial (KFUE Akademiska Sjukhuset): A randomized phase III trial in elderly patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival.

In addition I am local PI of the VALERIA trial in Uppsala testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma patients.

In January 2022 we started a new trial, the ALTAMIRA trial within the Nordic Mantle Cell lymphoma network investigating the next generation Brutons Tyrosine Kinase inhibitor acalabrutinib in a minimal residual disease (MRD) driven way.

With our ongoing trials we aim to give patients access to novel targeted drugs in Uppsala and Sweden.

In addition I am currently investigating the impact of selection to clinical trials and the molecular landscape in diagnostic and relapsed biopsies. PHD students interested in the field are welcome to contact me.

Recently we investigated comorbidities and causes of death in Mantle Cell Lymphoma patients, showing that the majority of patients dies from the lymphoma, although gender differences exists.

Comorbidities and causes of death in Mantle Cell Lymphoma - a nationwide population-based Glimelius I, Smedby KE, Eloranta S, Jerkeman M, Weibull CE

Br J Haematology, November 13 2019.

Pregnancy and the risk of cancer

In two recent articles published in International Journal of Cancer and a comprehensive review published in Journal of Internal Medicine the associations between pregnancies and later cancer risk in the mother is examined. In the first article we show that a full length pregnancy protects against epithelial ovarian cancer to a higher extent than a pregnancy resulting in preterm delivery. In the next article, we show a decreased risk of breast cancer for females experiencing high blood pressure prior to and during pregnancy. In the review we both illustrate and discuss different aspects of pregnancy and a later risk of several solid malignancies.

Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Sköld C, Bjørge T, Ekbom A, Engeland A, Gissler M, Grotmol T, Madanat-Harjuoja L, Gulbech Ording A, Stephansson O, Trabert B, Tretli S, Troisi R, Toft Sørensen H, Glimelius I.

Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581. [Epub ahead of print] PMID:29737528

Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.

Troisi R, Gulbech Ording A, Grotmol T, Glimelius I, Engeland A, Gissler M, Trabert B, Ekbom A, Madanat-Harjuoja L, Toft Sørensen H, Tretli S, Bjørge T.

Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600. [Epub ahead of print] PMID: 29752724

The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.

Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, Ording AG, Sköld C, Sørensen HT, Trabert B, Glimelius I.J Intern Med. 2018 May;283(5):430-445. doi: 10.1111/joim.12747. Epub 2018 Mar 25. PMID:29476569

Malignant Germ Cell Tumours - testicular cancer and non-epithelial ovarian cancer

We have a newly started research collaboration focusing on rare malignancies in young adults. We conduct research on risk and prognosis in testicular cancer and research about the rare non-epithelial ovarian cancer in women.

We conduct large register-based investigations and have collaborations with the SWENOTECA group, Sweden Norway Testicular Cancer, and Svenska Gynekologiska Cancergruppen. With those collaborations we gain knowledge and data from whole Sweden.

Please contact the directory administrator for the organization (department or similar) to correct possible errors in the information.

Ingrid Glimelius